At the molecular level, the combination therapy effectively inhibited the expression of p-MET, p-ERK, p-AKT, and p-mTOR in HCC cells and the c-MET/β-catenin mouse HCC lesions. This evidence concerns the gene AKT1 and hepatocellular carcinoma.